PD-1/PD-L1
PD-1/PD-L1 inhibitors are immune checkpoint inhibitors that block the interaction between the programmed cell death protein 1 (PD-1) on T cells and its ligand PD-L1 on cancer cells. This interaction normally suppresses the immune response and allows cancer cells to evade immune detection. By inhibiting PD-1/PD-L1, these inhibitors enhance the immune system's ability to recognize and destroy cancer cells, inducing apoptosis and tumor regression. PD-1/PD-L1 inhibitors are critical in immunotherapy research and cancer treatment. At CymitQuimica, we offer a range of high-quality PD-1/PD-L1 inhibitors to support your research in immuno-oncology, apoptosis, and cancer therapy.
Found 125 products of "PD-1/PD-L1"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
PD-L1-IN-7
CAS:<p>PD-L1-IN-7 (compound CB31) serves as a PD-L1 inhibitor, effectuating PD-L1 internalization and retention within cells. It restrains the PD-1/PD-L1 interaction (IC 50: 0.2 nM), alters glycosylation patterns, and facilitates PD-L1 degradation. Additionally, PD-L1-IN-7 enhances T cell infiltration, boosts T cell function, and augments the capacity to destroy tumor cells.</p>Formula:C46H50N6O7Color and Shape:SolidMolecular weight:798.93PD-1/PD-L1-IN-53
CAS:<p>PD-1/PD-L1-IN-53 (compound B3) serves as an inhibitor targeting both the PD-1/PD-L1 and VISTA signaling pathways. It is utilized in cancer research.</p>Formula:C31H37N3O4Color and Shape:SolidMolecular weight:515.64PD-L1/VISTA-IN-1
CAS:<p>PD-L1/VISTA-IN-1 (Compound P17) is an orally active dual inhibitor targeting PD-L1 and VISTA. It effectively hinders the PD-1/PD-L1 interaction (IC50: 0.1492 μM) and the VISTA pathway (KD: 0.2723 μM), leading to the reactivation of T cells. Additionally, PD-L1/VISTA-IN-1 exhibits antitumor activity.</p>Formula:C22H24N4O4Color and Shape:SolidMolecular weight:408.45Enpp-1-IN-25
CAS:<p>Enpp-1-IN-25 (Compound 30) is an ENPP1 inhibitor with an IC50 of 8.05 nM and exhibits low oral bioavailability. By inhibiting cGAMP degradation, it effectively activates the intracellular STING pathway. Enpp-1-IN-25 can enhance immune cell infiltration and type I interferon response in the tumor microenvironment, thereby increasing the antitumor efficacy of anti-PD-L1 antibodies. It is applicable for research in cancer immunotherapy.</p>Formula:C15H21N5O4SColor and Shape:SolidMolecular weight:367.423INCB086550
CAS:<p>INCB086550 (PD-1/PD-L1-IN-8) (example 24) is a PD-1/PD-L1 inhibitor, with an IC50 <= 10 nM.</p>Formula:C41H39N7O4Purity:98.49%Color and Shape:SolidMolecular weight:693.79
